首页> 美国卫生研究院文献>Molecules >Design Synthesis and Bioactivity Evaluation of 46-Disubstituted Pyrido32-
【2h】

Design Synthesis and Bioactivity Evaluation of 46-Disubstituted Pyrido32-

机译:46-二取代的吡啶的设计合成和生物活性评价32-

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Both HDACs and Mnks play important role in translating multiple oncogenic signaling pathways during oncogenesis. As HDAC and Mnk are highly expressed in a variety of tumors; thus simultaneous inhibit HDAC and Mnk can increase the inhibition of tumor cell proliferation and provide a new way of inhibiting tumor growth. Based on the previous work and the merge pharmacophore method; we designed and synthesized a series of 4,6-disubstituted pyrido[3,2-d]pyrimidine derivatives as HDAC and Mnk dual inhibitors. Among them; compound A12 displayed good HDAC and Mnk inhibitory activity. In vitro antiproliferative assay; compound A12 exhibited the best antiproliferative activity against human prostate cancer PC-3 cells. Docking study revealed that the pyrido[3,2-d]pyrimidine framework and hydroxamic acid motif of compound A12 were essential for maintaining the activity of HDAC and Mnk. These result indicated that A12 was a potent Mnk /HDAC inhibitor and will be further researched.
机译:HDACS和MNK均在蜂拥期地翻译多种致癌信号通路方面发挥着重要作用。由于HDAC和MNK在各种肿瘤中高度表达;因此,同时抑制HDAC和MNK可以增加肿瘤细胞增殖的抑制,并提供一种抑制肿瘤生长的新方法。基于以前的工作和合并药效线方法;我们设计和合成了一系列4,6-二取代的吡啶[3,2-D]嘧啶衍生物,作为HDAC和MNK双抑制剂。他们之中;化合物A12显示出良好的HDAC和MNK抑制活性。体外抗增殖试验;化合物A12表现出对人前列腺癌PC-3细胞的最佳抗增殖活性。对接研究表明,化合物A12的吡啶[3,2-D]嘧啶骨架和羟肟酸基序对于维持HDAC和MNK的活性是必不可少的。这些结果表明A12是一种有效的MNK / HDAC抑制剂,并将进一步研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号